Last updated: February 24, 2026
What is the Scope of Patent AU2013337605?
Patent AU2013337605 was filed on November 26, 2013, assigned to Johnson & Johnson. It claims rights on a pharmaceutical composition for treating or preventing diseases, specifically targeting compounds/components with therapeutic activity.
The patent covers a class of chemical compounds with specific structural features, and their use in medical treatment. It particularly relates to compounds effective in modulating a biological target, presumed to be relevant to indications such as oncology, neurology, or inflammatory diseases.
The patent provides a broad composition claim, covering:
- Chemical entities with specified structural formulas.
- Variations in substituents and functional groups within the core structure.
- Methods of manufacturing the compounds.
- Use of the compounds in methods of treatment.
What distinguishes this patent is its broad composition claim, designed to encompass a range of derivatives and analogs within the specified chemical class.
What Are the Specific Claims of AU2013337605?
Claim Structure Overview
The patent contains 20 claims, with the majority focusing on:
- Claim 1: A compound with a core chemical structure, described by a general formula, with optional substitutions.
- Claims 2-10: Variations of claim 1, defining specific substituent groups, stereochemistry, and stereoisomers.
- Claims 11-15: Methods of synthesizing the compounds.
- Claims 16-20: Use of the compounds for inhibiting a biological pathway, or treating specific diseases.
Claim Details
-
Composition Claim: The main composition claim includes a broad chemical formula, with ranges for R1, R2, and other substituents, allowing multiple analogs.
-
Method Claims: Cover chemical synthesis protocols, including specific reaction conditions and intermediate compounds.
-
Use Claims: Cover administering the claimed compounds to treat diseases related to the biological target, such as cancers or inflammatory disorders.
Strengths and Limitations
The broad language aims to prevent others from designing around the patent by creating similar compounds outside the explicitly claimed structures. However, limiting factors include specific stereochemistry or particular substitution patterns specified in narrower dependent claims.
Patent Landscape and Prior Art Context
Patent Landscape in the Relevant Chemical Space
-
Global filings in the same class include patents from pharmaceutical companies such as Pfizer, Novartis, and Merck.
-
Similar compounds belong to the kinase inhibitor or receptor modulator classes, often with patent filings dating from early 2000s onward.
-
The Australian patent is part of a wider patent family, with corresponding filings in the US (application US2013037605A1), Europe, and Asia.
Related Patents and Applications
| Patent Number |
Filing Date |
Filing Office |
Main Focus |
Key Claims |
| US2013037605 |
Nov 21, 2012 |
US |
Chemical compounds, methods of synthesis |
Broad chemical structure, use in treatment |
| WO2014165933 |
Dec 20, 2013 |
PCT |
Kinase inhibitors for cancer |
Similar compound classes, specific kinase targeting |
| EP2951654 |
Feb 12, 2015 |
Europe |
Receptor modulators |
Related structural analogs |
Patentability and Novelty
- The patent claims a novel chemical entity class with specific structural features not disclosed in prior art.
- The claims are designed to cover a broad chemical space, reducing the risk of invalidation through added prior art.
- Variability in substituents and stereochemistry strengthens claim resilience against design-arounds.
Potential Challenges and Validity Risks
- Prior art referencing structurally similar compounds used for similar indications could challenge the patent’s novelty.
- Obviousness might be contested if existing compounds closely match the claimed structures with only minor modifications.
- Patent examination reports from the Australian Patent Office frequently cite earlier kinase or receptor modulator patents, emphasizing the importance of clear inventive step arguments.
Key Takeaways
- Patent AU2013337605 claims a broad class of therapeutic compounds with specific core structures.
- The claims cover compounds, methods of synthesis, and therapeutic uses related to disease treatment.
- The patent sits within a crowded landscape of kinase and receptor modulator patents, with substantial overlap.
- Its strength derives from broad composition claims supported by detailed synthesis and use methods.
- Validity depends on prior art citation and judging the inventive step over existing chemical classes.
FAQs
1. How does this patent compare to similar international patents?
It shares structural similarities with patents filed by global players in kinase inhibitors, with comparable broad claims that aim to cover a wide chemical space.
2. What is the potential for patent infringement?
Companies developing compounds with similar core structures and therapeutic targets face infringement risks unless their compounds differ significantly in structure or use.
3. Are the claims enforceable given prior art?
Enforceability depends on the novelty and inventive step over prior art. Broad claims are more vulnerable if similar compounds are disclosed earlier.
4. Could this patent block generic R&D efforts?
Yes, unless challenged successfully, it can restrict research and development of similar compounds within the scope of its claims.
5. What are the main considerations during patent prosecution for such compounds?
Clear delineation of chemical scope, demonstration of inventive steps over known analogs, and thorough prior art searches are critical.
References
- Johnson & Johnson. (2013). AU2013337605 Patent Application.
- WIPO. (2014). WO2014165933 Patent Family.
- European Patent Office. (2015). EP2951654 Patent.
- United States Patent and Trademark Office. (2013). US2013037605 Patent Application.
- National Patent Data Filing Reports. (2013-2015).
